Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H25N7O2 |
| Molecular Weight | 383.4475 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N
InChI
InChIKey=LDXYBEHACFJIEL-HNNXBMFYSA-N
InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23337530
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23337530
Anagliptin is a DPP-4 inhibitor developed for the treatment of type 2 diabetes mellitus. The drug was approved in Japan under the name Suiny and now it is being tested in the USA.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats. | 2013 |
|
| Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. | 2013 Mar |
|
| Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. | 2013 May |
|
| Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study. | 2015 Feb |
Patents
Sample Use Guides
In general, for adults, take 1 tablet (100mg of anagliptin) at a time, twice a day, in the morning and in the evening. If the effect is insufficient, a dose may be increased up to 2 tablets (200mg) at a time, adequately monitoring the condition.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98086
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID401045689
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
SUB93457
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
Anagliptin
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
DB12417
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
44513473
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
4896
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
9246
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
100000141574
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
C96202
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
K726J96838
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
739366-20-2
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY | |||
|
m11709
Created by
admin on Fri Dec 15 17:59:16 UTC 2023 , Edited by admin on Fri Dec 15 17:59:16 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
